Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep 6;115(6):649-54.
doi: 10.1038/bjc.2016.222. Epub 2016 Jul 28.

FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience

Muralidharan K Chllamma  1 , Natalie Cook  1   2 , Neesha C Dhani  1 , Kazim Giby  1 , Anna Dodd  1 , Lisa Wang  1 , David W Hedley  1 , Malcolm J Moore  1   3 , Jennifer J Knox  1
Affiliations

FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience

Muralidharan K Chllamma et al. Br J Cancer. .

Abstract

Background: FOLFIRINOX has been shown to significantly increase both overall survival (OS) and progression-free survival (PFS) in metastatic pancreas cancer. There is limited data regarding the treatment of locally advanced pancreatic cancer. We present a retrospective study of patients with both locally advanced and metastatic pancreas cancer using FOLFIRINOX as first-line therapy in our centre.

Methods: This is a retrospective review of patients treated with FOLFIRINOX for pancreatic cancer at Princess Margaret Cancer Centre, between December 2011 and July 2014. The primary objective was to evaluate the efficacy and safety of FOLFIRINOX when used with dose modifications.

Results: One hundred two patients were identified; 66 metastatic and 36 locally advanced. Sixty-eight per cent of patients initiated treatment with a dose reduction. The median (95% CI) OS in the metastatic group was 13.1 (6.3-16.1) months with full dose and 12.9 (10.3-30.1) months with modified dose. The median (95% CI) OS in the locally advanced group was 11.1 (6.1-not reached) months with full dose and 23 (not reached-not reached) months with modified dose. The median (95% CI) PFS in the metastatic group was 6.2 (4.9-15.2) months with full dose and 8.7 (5.7-12.9) months with modified dose. The median (95% CI) PFS in the locally advanced group was 11.1 (3.1-not reached) months with full dose and 10.4 (6.8-not reached) months with modified dose. Grade 3/4 haematologic adverse events were observed in 43% of patients. Grade 3/4 non-haematologic adverse events were observed in 28% of patients. Patient well-being significantly improved from baseline to cycle 4 (P=0.002).

Conclusions: Efficacy was achievable with dose-modified FOLFIRINOX in daily setting. The safety of FOLFIRINOX remains a concern with a high rate of grades 3 and 4 neutropaenia despite dose reduction.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Bar chart showing starting and overall average dose intensity for bolus 5-Fluorouracil, oaxaliplatin, irinotecan and infusional 5-fluorouracil.
Figure 2
Figure 2
Kaplan–Meier plots of overall survival. (A) Median OS with full dose and modified dose in metastatic patients. Median (95% CI) OS with full dose was 13.1 (6.3–16.1) months and with modified dose was 12.9 (10.3–30.1). (B) Median OS with full dose and modified dose in non-metastatic patients. Median (95% CI) OS with full dose was 11.1 (6.1–not reached) months and with modified dose 23(not reached–not reached) months.
Figure 3
Figure 3
Kaplan–Meier plots of progression-free survival. (A) Median PFS with full dose and modified dose in metastatic patients. Median (95% CI) OS with full dose was 6.2 (4.9–15.2) months and with modified dose was 8.7 (5.7–12.9) months. (B) Median PFS with full dose and modified dose in non-metastatic patients. Median (95% CI) OS with full dose was 11.1 (3.1–not reached) months and with modified dose 10.4 (6.8–not reached) months.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Amirealut C, Beaudet J, Gaudet G, Raymond N, Ayoub J-PM, Letourneau R, Loungnarath R, Tehfe MA, Aubin F (2014) FOLFIRINOX in the real world setting: the multicentric experience of six Canadian Institutions. J Clin Oncol 32(suppl 3): abstract 367.
    1. Attard CL, Brown S, Alloul K, Moore MJ (2014) Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer. Curr Oncol 21: e41–e51. - PMC - PubMed
    1. Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Ellison EC, Bloomston M, Bekaii-Saab T (2015) Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol 22: 1153–1159. - PMC - PubMed
    1. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7: 6–9. - PubMed
    1. Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403–2413. - PubMed

MeSH terms